These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 35413245)

  • 1. Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity.
    Maruhashi T; Sugiura D; Okazaki IM; Shimizu K; Maeda TK; Ikubo J; Yoshikawa H; Maenaka K; Ishimaru N; Kosako H; Takemoto T; Okazaki T
    Immunity; 2022 May; 55(5):912-924.e8. PubMed ID: 35413245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.
    Wang J; Sanmamed MF; Datar I; Su TT; Ji L; Sun J; Chen L; Chen Y; Zhu G; Yin W; Zheng L; Zhou T; Badri T; Yao S; Zhu S; Boto A; Sznol M; Melero I; Vignali DAA; Schalper K; Chen L
    Cell; 2019 Jan; 176(1-2):334-347.e12. PubMed ID: 30580966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LAG-3 inhibits the activation of CD4
    Maruhashi T; Okazaki IM; Sugiura D; Takahashi S; Maeda TK; Shimizu K; Okazaki T
    Nat Immunol; 2018 Dec; 19(12):1415-1426. PubMed ID: 30349037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel LAG3 neutralizing antibody improves cancer immunotherapy by dual inhibition of MHC-II and FGL1 ligand binding.
    Zuo D; Zhu Y; Wang K; Qin Y; Su Y; Lan S; Li Y; Dong S; Liang Y; Feng M
    Biomed Pharmacother; 2024 Jun; 175():116782. PubMed ID: 38776682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes.
    Hannier S; Triebel F
    Int Immunol; 1999 Nov; 11(11):1745-52. PubMed ID: 10545478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition.
    Ming Q; Celias DP; Wu C; Cole AR; Singh S; Mason C; Dong S; Tran TH; Amarasinghe GK; Ruffell B; Luca VC
    Nat Immunol; 2022 Jul; 23(7):1031-1041. PubMed ID: 35761082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinogen-Like Protein 1 Serves as an Anti-Inflammatory Agent for Collagen-Induced Arthritis Therapy in Mice.
    Lin WW; Ho KW; Su HH; Fang TF; Tzou SC; Chen IJ; Lu YC; Chang MS; Tsai YC; Liu ES; Su YC; Wang YT; Cheng TL; Huang HK
    Front Immunol; 2021; 12():767868. PubMed ID: 34975855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of LAG-3/FGL1 pathway on immune evasive contexture and clinical outcomes in advanced urothelial carcinoma.
    Yoshida T; Nakamoto T; Atsumi N; Ohe C; Sano T; Yasukochi Y; Tsuta K; Kinoshita H
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39043605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts.
    Demeure CE; Wolfers J; Martin-Garcia N; Gaulard P; Triebel F
    Eur J Cancer; 2001 Sep; 37(13):1709-18. PubMed ID: 11527700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function.
    Silberstein JL; Du J; Chan KW; Frank JA; Mathews II; Kim YB; You J; Lu Q; Liu J; Philips EA; Liu P; Rao E; Fernandez D; Rodriguez GE; Kong XP; Wang J; Cochran JR
    Proc Natl Acad Sci U S A; 2024 Mar; 121(12):e2310866121. PubMed ID: 38483996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.
    Johnson DB; Nixon MJ; Wang Y; Wang DY; Castellanos E; Estrada MV; Ericsson-Gonzalez PI; Cote CH; Salgado R; Sanchez V; Dean PT; Opalenik SR; Schreeder DM; Rimm DL; Kim JY; Bordeaux J; Loi S; Horn L; Sanders ME; Ferrell PB; Xu Y; Sosman JA; Davis RS; Balko JM
    JCI Insight; 2018 Dec; 3(24):. PubMed ID: 30568030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy.
    Qian Y; Sun Y; Shi P; Zhou X; Zhang Q; Dong Q; Jin S; Qiu L; Niu X; Zhou X; Zhao W; Wu Y; Zhai W; Gao Y
    Acta Pharm Sin B; 2024 Mar; 14(3):1150-1165. PubMed ID: 38486998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target.
    Qian W; Zhao M; Wang R; Li H
    J Hematol Oncol; 2021 Sep; 14(1):147. PubMed ID: 34526102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ligand-dependent suppression of TCR signaling by the immune checkpoint receptor LAG3 depends on the cytoplasmic RRFSALE motif.
    Aigner-Radakovics K; De Sousa Linhares A; Salzer B; Lehner M; Izadi S; Castilho A; Pickl WF; Leitner J; Steinberger P
    Sci Signal; 2023 Oct; 16(805):eadg2610. PubMed ID: 37788323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocyte-derived FGL1 accelerates liver metastasis and tumor growth by inhibiting CD8+ T and NK cells.
    Xi F; Sun H; Peng H; Lian Z; Wei H; Tian Z; Sun R; Chen Y
    JCI Insight; 2024 May; 9(13):. PubMed ID: 38973608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immune checkpoint receptor LAG3: Structure, function, and target for cancer immunotherapy.
    Mariuzza RA; Shahid S; Karade SS
    J Biol Chem; 2024 May; 300(5):107241. PubMed ID: 38556085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation.
    Maeda TK; Sugiura D; Okazaki IM; Maruhashi T; Okazaki T
    J Biol Chem; 2019 Apr; 294(15):6017-6026. PubMed ID: 30760527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis.
    Hemon P; Jean-Louis F; Ramgolam K; Brignone C; Viguier M; Bachelez H; Triebel F; Charron D; Aoudjit F; Al-Daccak R; Michel L
    J Immunol; 2011 May; 186(9):5173-83. PubMed ID: 21441454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T Cell Receptor Binding to a pMHCII Ligand Is Kinetically Distinct from and Independent of CD4.
    Xiong Y; Kern P; Chang H; Reinherz E
    J Biol Chem; 2001 Feb; 276(8):5659-67. PubMed ID: 11106664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characterization of HLA class II binding to the LAG-3 T cell co-inhibitory receptor.
    MacLachlan BJ; Mason GH; Greenshields-Watson A; Triebel F; Gallimore A; Cole DK; Godkin A
    Eur J Immunol; 2021 Feb; 51(2):331-341. PubMed ID: 32920841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.